NAD+ vs GLP3 R

This pairing produces more bad information than almost any other in a research catalogue, because the two compounds sit in completely different chemical classes while both being filed under "metabolic." Here is what goes wrong, in the order it usually goes wrong.

Proxiva Formulation DeskBlends, fill weights and multi-component products

Failure 1 — treating them as alternatives

They are not comparable in that way, and the reason is categorical rather than a matter of degree.

NAD+ is a coenzyme. Nicotinamide adenine dinucleotide is present in every living cell, cycling between oxidised and reduced forms as it carries electrons through metabolic reactions. It does not signal anything. It is a working part of the machinery — and it is also a substrate for sirtuins and PARPs, which consume it rather than merely using it catalytically. That consumption is why availability becomes a research question at all.

GLP-3 R is a receptor agonist. It binds receptors and triggers them. Specifically three: GLP-1, GIP and glucagon. It participates in no metabolic reaction itself.

One is a reagent. The other is a message. Asking which is better is asking whether a battery outperforms a switch — and any source that answers it has told you something about their standards rather than about the compounds.

Failure 2 — a certificate that reports a sequence for NAD+

NAD+ has no amino-acid sequence. It is nicotinamide joined to adenine through two riboses and a pair of phosphates — a defined chemical structure, identified as such.

So a certificate reporting a "sequence" for it was produced from a peptide template rather than from analysis of the compound. That single observation should determine how much weight you give everything else on the page, because it means the paperwork was generated rather than measured.

This is not a rare error. NAD+ sits on peptide shelves, gets ordered through peptide workflows, and receives peptide-shaped documentation from suppliers whose analytical process assumes everything they sell is a chain of amino acids.

What a correct NAD+ certificate carries instead:

• HPLC purity with the chromatogram image
• Identity confirmed against a chemical structure or molecular formula, not a sequence
• Batch number matching the vial label
• Named testing laboratory, independent of synthesis
• Residual solvents appropriate to its synthetic route
• Water content, since it affects net compound per stated milligram

The same trap catches 5-Amino-1MQ, another non-peptide sold on peptide shelves — covered in the 5-Amino-1MQ guide.

Failure 3 — a mass derived from a bare sequence

The mirror-image error, on the other side of the comparison.

GLP-3 R is modified. Modifications weigh something. So the number a mass spectrometer should be compared against is not the number you get by adding up the amino acids.

What this looks like on a bad certificate: a tidy sequence, a plausible mass beneath it, and no indication that either accounts for what was attached to the molecule. Nothing on the page looks wrong. The figure was simply calculated for a different substance — an unmodified version of this peptide that nobody sells.

You cannot catch this by reading harder. You catch it by asking one question: which theoretical mass was this compared against, and does it include the modification? A supplier who has actually run the analysis answers immediately. One working from a template cannot, because the template never asked.

The second issue at this chain length is quieter still. Long syntheses accumulate deletion sequences — chains short by a residue — and they elute right beside the target. A purity percentage folds them into a single number that looks fine. The chromatogram does not: clustered peaks against the main one mean they were never separated.

So on a long modified peptide, two things are true at once. The mass may describe a molecule that does not exist, and the purity may describe a mixture. Neither is visible without asking.

Detail in the GLP-3 pen guide and how to read a certificate of analysis.

Failure 4 — comparing them per milligram

Cost per milligram is the right way to compare the same compound across suppliers. It is a poor way to compare two compounds, and a meaningless way to compare two compound classes.

NAD+ is consumed in bulk. Cells maintain it at concentrations far above anything a receptor agonist operates at, because it is a working reagent rather than a signal. Research quantities follow the biology.

Receptor agonists act at far lower concentrations by design. Binding a receptor does not require bulk.

So the same milligram means different things. A milligram of a bulk reagent and a milligram of a signalling molecule are not comparable units of anything, and dividing price by weight for each produces two numbers that cannot be meaningfully set beside one another.

What is valid to compare across both: whether the stated weight is net compound or includes water and counterion — HPLC purity measures neither, so the headline figure always overstates active material. Ask for both.

What the naming actually means

Worth settling because it drives a great deal of confusion in this corner of a catalogue.

There is no GLP-3 receptor. The label counts receptors engaged, not a receptor type:

Each additional receptor is a harder design problem — the molecule must satisfy several sets of structural constraints simultaneously — which is what the price ladder across the three reflects, rather than scarcity.

Storing two different kinds of thing

The instinct on a peptide shelf is to apply peptide rules to everything on it. That instinct is wrong here in one direction and insufficient in the other.

NAD+ is not a peptide. Its stability is governed by different chemistry, and peptide handling rules are conservative rather than correct for it. Follow the supplier's own guidance; where none exists, peptide-grade care errs safe but is not evidence-based.

GLP-3 R needs more than standard care, not less. A long modified chain has many sites where hydrolysis and oxidation can take hold, so time in solution costs it more than it costs a short peptide. Reconstitute to consumption, not to the vial.

The pen concentrates that. Its contents have been dissolved since a fill date the label usually omits, so some unknown fraction of the material's solution life is already spent before it reaches you. For a long peptide that unknown is worth asking about; for a tripeptide it would barely matter.

Procedure in reconstituting research peptides, and the format question in pens versus vials.

Failure 5 — assuming a shelf label describes a mechanism

The error underneath the other four, and the one worth carrying beyond this pair.

Both compounds sit under "metabolic" in a research catalogue. That grouping is real as a shelf label and says nothing about how either works. NAD+ arrived there from foundational biochemistry — it was described as a fermentation coenzyme in the early twentieth century, taught in every undergraduate course, and became a catalogue item only when work on sirtuins made availability interesting. GLP-3 R arrived from targeted drug design, decades later, by a completely unrelated route.

Catalogue categories describe what sells together, not what acts alike. A supplier groups by what a buyer is likely to want in the same order, which is a commercial judgement rather than a biochemical one.

Recognising that dissolves most bad comparisons before they start. The useful question is never "which of these two is better" but "which mechanism is my protocol examining, and which compound operates there." Two things filed together may operate at completely different levels of biology — as a coenzyme and a receptor agonist do.

The same reasoning applies across the catalogue. NAD+ and GHK-Cu both appear under longevity; one is a redox coenzyme, the other a copper-bound tripeptide acting on extracellular matrix. MOTS-c and SLU-PP-332 both appear under mitochondrial work; one is a peptide requiring reconstitution, the other an oral tablet. Neither pairing shares a mechanism.

When a comparison feels difficult to make cleanly, the usual reason is that the two things were never in the same category to begin with — only on the same shelf.

Frequently asked questions

Research use only. All products referenced on this page are sold strictly for laboratory and research purposes. They are not drugs, foods, cosmetics, or medical devices, and they are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. Handling should be performed only by qualified individuals in an appropriate laboratory setting.